...director of medicinal chemistry at Bristol-Myers Squibb Co. and co-founded Tetraphase and fellow anti-infectives company Vicuron Pharmaceuticals Inc....

...decision in the EU in 1H15. The company gained Dalvance through its 2009 acquisition of Vicuron Pharmaceuticals Inc....

...decision in the EU in 1H15. The company gained Dalvance through its 2009 acquisition of Vicuron Pharmaceuticals Inc....

...decision in the EU in 1H15. The company gained Dalvance through its 2009 acquisition of Vicuron Pharmaceuticals Inc....

...years of market exclusivity, if approved. Durata gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....

...cSSTI) caused by susceptible Gram-positive microorganisms. Durata gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....

...of market exclusivity, if approved. The company gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....

...see BioCentury, Nov. 12, 2012). The company gained the product through its 2009 acquisition of Vicuron Pharmaceuticals Inc....

...in 1H15. The company gained the second-generation once-weekly glycopeptide antibiotic through its 2009 acquisition of Vicuron Pharmaceuticals Inc....

...year end. The company gained the second-generation once-weekly glycopeptide antibiotic through its 2009 acquisition of Vicuron Pharmaceuticals Inc....